News & Events about Annexon Inc.
Annexon, Inc. (NASDAQ:ANNX Get Rating) Equities researchers at Jefferies Financial Group issued their FY2027 earnings per share estimates for shares of Annexon in a report released on Tuesday, January 10th. Jefferies Financial Group analyst S. Jeong forecasts that the company will post earnings of...
Mid-stage and Pivotal Trials of ANX005, ANX007 and ANX1502 Poised to Achieve Numerous Catalysts in Multiple Disease Indications Well-Capitalized with Operating Runway into 2025 Company to Present Pipeline Updates at 41st Annual J.P. Morgan Healthcare Conferenceon January 11, 2023, at 7:30 a.m. PT ...
BRISBANE, Calif., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that ...
Globe Newswire
6 months ago
BRISBANE, Calif., July 08, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that it ...
Ticker Report
11 months ago
Geode Capital Management LLC increased its position in shares of Annexon, Inc. (NASDAQ:ANNX Get Rating) by 4.8% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 425,043 shares of the companys stock after ...